

Rhythm Completes Reagent Development Program



- **Reagent capability established for lead biomarkers**
- **Manufacturing scale up commenced**
- **Assay and kit development commenced & on track for completion in 2019**

5 December 2018, Melbourne: Medical diagnostics company Rhythm Biosciences Limited (ASX: RHY) has successfully generated reagents (antibodies and proteins) required for the lead biomarkers for its colorectal cancer detecting blood test, ColoSTAT®. This completes the reagent development establishment and shifts the company's attention to manufacturing scale-up and assay optimisation.

Rhythm now has seed banks of antibody-producing cell lines for the detection of its lead target biomarkers. This work provides key insights into the growth and productivity of these cell lines, that will be key to inform manufacturing scale up and subsequent optimisation and ongoing development.

"This is another key milestone completed by Rhythm. Next steps are to scale up the manufacture, optimise these key reagents and integrate them into a robust, reproducible ColoSTAT® test. That will be verified in Study 6 which is on track for completion in 2019" said Rhythm CEO Glenn Gilbert.

Ends

For further information please contact:

Glenn Gilbert
Chief Executive Officer
+61 3 8256 2880

Shane Tanner
Chairman
+61 411 107 099

Media Contact:

Rudi Michelson
Monsoon Communications
+61 3 9620 3333

About Rhythm Biosciences

ASX-listed Rhythm Biosciences is developing and commercialising a screening and diagnostic tool for the early detection of colorectal cancer, the third biggest cause of cancer-related deaths globally.

Rhythm's lead product, ColoSTAT[®], is intended to be a simple, affordable, minimally invasive and effective blood test. It is expected to be comparable to, if not better than the current standard of care, the faecal immunochemical test (FIT), at a lower cost. ColoSTAT[®] also provides an alternative for those who choose not to or are unable to be assessed using standard screening programs.

ColoSTAT[®] is designed to be used easily by laboratories without the need for additional operator training or additional infrastructure.

ColoSTAT[®] has the potential to play an important role in reducing the morbidity and mortality rates and healthcare costs associated with colorectal cancer.